Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine vs FOLFOX in Metastatic Pancreatic Cancer (Panc001)
NCT01586611Phase 3Unknown
- Sponsor
- American Health Staffing Group
- Start
- Jun 2012
- Primary completion
- Apr 2015
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin, fluorouracil and folinic acid in pancreatic adenocarcinoma (PDAC), sponsored by American Health Staffing Group. Primary endpoint: Progression Free Survival at 2 years. Status: unknown.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01586611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01586611.